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Abstract 
 
Despite the well documented benefit of echocardiography 
in  acute  coronary  syndromes,  its  wide-scale  use  in  the 
Caribbean  is  limited  by  access,  health  literacy  and 
affordability.  Because  of  the  limited  use  of 
echocardiography  in  the  region,  routine  complications  of 
acute myocardial infarction (AMI) are not fully appreciated 
and may go unrecognized, further contributing to increased 
cardiovascular  morbidity  and  mortality.  It  is  therefore 
necessary to bring focus to this common clinical condition 
and  highlight  the  clinical  utility  of  echocardiography  in 
facilitating timely and accurate diagnosis. We report here a 
case of large left ventricular (LV) thrombus in a patient with 
AMI.  Coronary  angiography  showed  completely  occluded 
left anterior descending artery (LAD) with angiographically 
normal  remaining  vessels.  Immediate  anticoagulation  was 
commenced with heparin and overlapped with warfarin. No 
Primary Angioplasty (PA) was done based on the evidence 
from  occluded  artery  trial.  LV  thrombus  was  completely 
resolved  on  echocardiography  at  three  months.  No 
evidence  of  thrombo-embolism  was  found  during  the 
resolution of LV thrombus. 
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Background 
LV thrombus is a well recognized complication of AMI. It is 
estimated that 40-60% of patients with large anterior wall 
MI  will  develop  a  LV  thrombus.
1,2  Accurate  and  timely 
detection  is  important  as  it  poses  a  high  risk  for 
thromboembolic  events
3,4  which  can  be  prevented  by 
systemic  anticoagulation.
5,6  Two-dimensional 
echocardiography has played a pivotal role in defining the 
natural history of thrombus formation in post MI patients. 
Risk  factors  for  the  development  of  LV  thrombus  include 
age, infarct location, infarct number, size and extent, and 
impairment in global or regional LV function (i.e. ejection 
fraction <40%). It occurs most commonly in anterior wall MI 
compared to non-anterior wall MI.
7 We report here a case 
of large LV thrombus in a 61-year-old male with extensive 
anterior  wall  MI  describing  the  diagnosis,  therapeutic 
options, prognosis, and the practical strategies to prevent 
embolic complications.  
 
Case details 
A  61-year-old  male  patient  with  multiple  risk  factors  for 
coronary  artery  disease  was  referred  to  our  facility  for 
echocardiography,  three  days  after  his  admission  to  local 
public hospital for retrosternal chest pain. Even though the 
patient  presented  at  the  local  public  hospital  within  two 
hours  of  symptom  onset  and  was  at  the  time  of 
presentation diagnosed (by 12 lead electrocardiogram and 
cardiac  enzyme  assay)  with  acute  extensive  anterior  wall 
MI, thrombolytic therapy (TT) was not given and the patient 
was  not  referred  for  percutaneous  intervention  because 
these services were not available at the local public hospital.  
In  addition,  entrenched  local  practice  patterns  favored  a 
conservative  approach  despite  evidence  to  the  contrary. 
Attempted  transfer  to  an  affiliated  tertiary  university 
hospital  was  unsuccessful  due  to  bureaucratic  and 
structural  bottlenecks  further  delaying  appropriate  care 
with increasing morbidity and mortality risk for the patient. 
The patient was only transferred to our private facility after 
three days of delayed diagnostic testing and treatment. An 
echocardiogram  was  performed  at  our  facility  which 
demonstrated  dilated  LV  with  severely  reduced  systolic 
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function with an ejection fraction (EF) of 30-35%. Important 
regional  wall  motion  abnormalities  were  present  with 
akinesis  of  anteroseptal  wall  and  LV  apex,  and  severe 
hypokinesis  of  the  lateral  wall.  Both  findings  were 
consistent with a recent extensive anterior wall MI. A large 
fresh  apical  thrombus  was  noted  (Figure  1a)  with 
spontaneous echo contrast,  providing  further evidence of 
low  flow  state.  Coronary  angiography  (Figure  2)  was 
recommended  and  performed  on  the  same  day  which 
demonstrated complete occlusion of LAD at its  origin but 
angiographically normal left main (LM), left circumflex (LCX) 
and  dominant  right  coronary  arteries  (RCA)  without  any 
significant  collateral  circulation.  The  patient  was  then 
admitted  to  a  private  hospital  and  anticoagulation  was 
initiated  with  low  molecular  weight  heparin  with  a 
subcutaneous enoxaparin at a dose of 2mg/Kg given twice 
daily.  Oral  warfarin  was  started  and  antiplatelet  agents 
were continued. A repeat echocardiogram was performed 
prior  to  discharge  after  seven  days  of  overlap  which 
confirmed  a  resolving  thrombus  and  no  evidence  of  new 
thrombus  formation.  He  was  discharged  after  we  were 
satisfied  that  the  repeated  international  normalised  ratio 
(INR) values were within the therapeutic range (2-3). Dual 
antiplatelet  therapy  was  also  continued  and  his  INR  was 
carefully  monitored  as  an  outpatient.  Repeat 
echocardiograms were performed at the follow-up visits at 
six  weeks  (Figure  1b)  and  three  months  (Figure  1c)  after 
discharge. These showed complete resolution of the large 
apical thrombus at three months with no evidence of new 
thrombus  formation.  Warfarin  therapy  was  continued  for 
six months and then stopped. 
 
Discussion 
LV thrombus is a serious complication of AMI, with most 
thrombi developing during the first two weeks (median five 
to six days) after the initial AMI.
3 In patients with extensive 
anterior wall MI, the development of thrombus may start as 
early  as  a  few  hours  after  MI  evolving  in  to  full  blown 
thrombus  by  the  third  to  fifth  day.  LV  thrombus  was 
diagnosed in our patient when  the initial echocardiogram 
was undertaken (three days after presentation) and we are 
therefore  uncertain  as  to  when  the  thrombus  first 
developed – it is possible that it was formed within the first 
24 hours given the extensive transmural myocardial injury. 
While  many  patients  will  develop  thrombi  while  still 
hospitalised, it has been reported that patients with AMI 
may develop a new thrombus after the hospital discharge 
especially in patients with severe LV dysfunction
8 and hence 
serial  echocardiograms  should  be  considered  in  such 
patients. The incidence of LV thrombus in the current era of 
reperfusion  therapy  is  variable.  Several  studies  have 
reported  the  decreased  incidence  of  LV  thrombus  in 
patients treated with either TT9
9,10, or PA
11,12 compared to 
those who did not receive reperfusion therapy. Vaitkus et 
al
5 in a meta-analysis have reported the reduction in the 
incidence  LV  thrombus  with  TT,  which  however  did  not 
achieve statistical significance. Osherov et al,
13 in a recent 
study compared the incidence of LV thrombus in patients 
treated with PA, TT and conservative therapy respectively, 
and reported that in the current era of rapid reperfusion by 
PA,  the  rate  of  thrombus  formation  is  similar  to  that 
reported in the past and no difference was noted compared 
to those treated with either conservatively or thrombolysis.  
 
Two-dimensional  non-contrast  transthoracic 
echocardiography  (TTE)  is  the  most  commonly  used 
technique for the clinical identification and follow-up of LV 
thrombi based on anatomical appearance. It has sensitivity 
and a specificity of 92–95% and 86–88% respectively for the 
diagnosis of LV thrombs.
14,15  
 
Figures  1a-c:  Echocardiogram  showing  the  size  of  LV 
thrombus at third day, sixth week and end of third month 
after AMI. Arrows indicate LV thrombus.  
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Figure  2:  Angiogram  (day  3)  showing  the  completely 
occluded LAD at the ostium 
      
 
Despite the high accuracy it can be technically difficult in 
some  patients  because  of  the  difficulty  in  discerning  the 
myocardium-thrombus  interface,  limited  near  field 
resolution of the apex, or difficulty in obtaining images of 
the true apex. Recent studies have reported that up to two-
thirds of LV thrombi can be missed by routine non-contrast 
echo,  with  mural  or  small  thrombi  least  likely  to  be 
detected.
16-1  8Application  of  advanced  echocardiographic 
techniques  such  as  harmonic  imaging  and  contrast 
echocardiography  improves  the  diagnostic  detection  by 
improving  the  LV  endocardial  border  definition,  cavity 
delineation,  and  overall  image  quality  and  can  be 
recommended.
19,20 Recent advances in cardiac imaging have 
enabled assessment of vascular supply, allowing thrombi to 
be identified by avascular tissue characteristics rather than 
anatomical  criteria  resulting  from  absence  of  contrast 
uptake.  Magnetic  resonance  imaging  (MRI)  with  contrast 
enhancement has shown promise in the identification of LV 
thrombus, having greater sensitivity and specificity than TTE 
and  trans-esophageal  echocardiography  (TEE).
16  In 
particular,  the  delayed  contrast-enhanced  MRI  technique 
using  an  inversion  recovery  pulse  to  suppress  signal  of 
normal myocardium has been shown to be highly beneficial 
in  detecting  intracavitary  thrombi  (which  are  dark),  in 
addition  to  being  an  excellent  technique  for  depicting 
adjacent MI and scarring. Weinsoft et al
17 in a comparison 
study  involving  121  patients  using  delayed  contrast-
enhanced MRI as a reference standard for detection of LV 
thrombus reported sensitivities of 33%, 61%, and 79% for 
echo, contrast echo and cine-CMR respectively. 
 
LV thrombus increases the risk for embolic complications. 
The reported frequency of occurrence of stroke in patients 
with AMI is 1.5% to 3.6% which is thought to be embolic 
from a mural thrombus.
5 Characteristics of thrombi that are 
associated with high risk for embolisation include mobility, 
protuberance,  immaturity,  filamentous  nature,  variable 
echo density with central liquefaction and irregular borders. 
Studies have shown that 55 % of mobile thrombi and 45% of 
protruding  thrombi  embolize  compared  to  10%  immobile 
and 7% non-protruding thrombi
21,22 respectively. 
 
In  patients  with  LV  thrombus  or  severe  LV  dysfunction 
complicating  a  recent  MI,  aggressive  anti-thrombotic 
therapy  with  unfractionated  or  low  molecular  heparin 
should  be immediately  started and long term overlapped 
with warfarin. High dose intravenous heparin therapy
23 with 
or without warfarin has been shown to be associated with 
reduction in the rate of thrombus formation and embolic 
phenomena  during  acute  MI.  Vaitkus  et  al.
5  in  a  meta-
analysis  have  shown  that  the  administration  of 
anticoagulation  is  associated  with  significant  reduction  in 
embolic  events.  ACC/AHA  gave  a  class  I  recommendation 
that  intravenous  unfractioned  heparin  or  low  molecular 
weight heparin should be used in patients after ST-elevation 
MI who are at high risk for systemic emboli (occurrence of a 
large anterior infarction, documentation of thrombus in the 
LV  by  echocardiography,  history  of  a  previous  embolic 
event,  and  atrial  fibrillation).
24  Treatment  with  warfarin 
without concomitant high dose heparin has been associated 
with  high  prevalence  of  LV  thrombus  and  embolic 
complications.  Kontny  et  al.,
25  in  a  study  involving  229 
patients, reported an increased prevalence of LV thrombus 
formation  in  patients  treated  with  warfarin  without 
concomitant  high-dose  heparin  therapy  and  a  similar  but 
non-significant  difference  was  observed  in  patients  who 
were  given  low-dose  heparin.  The  ability  of  warfarin  to 
reduce the coagulation inhibitors (protein C and S) faster 
than the coagulation factors (Prothrombin-II) may result in a 
transient  hypercoagulable  state  at  the  beginning  of  the 
therapy
26,27 and hence it should ideally be overlapped with 
heparin  to  prevent  thromboembolic  complications.  Once 
the therapeutic INR is reached heparin can be discontinued 
and oral anticoagulation continued for at least three to six 
months or  indefinitely. Antiplatelet therapy has not been 
shown to be associated with reduced incidence of embolic 
complications.
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The  recommendation  of  TT  for  the  treatment  of  LV 
thrombus is controversial. Available data is conflicting with 
a number of studies showing their beneficial effect
9,10 and a 
number of other studies
28,29 showing the contrary. Choice of 
thrombolytic  agent  did  not  have  any  impact  on  the  LV 
thrombus  formation.
30  Moreover,  TT  can  cause  increased 
mobility  of  apical  thrombus  resulting  in  an  increased 
tendency towards embolisation.
31 Overall, no consensus has 
been  achieved  regarding  the  efficacy  of  TT  for  the 
treatment  of  LV  thrombus.  Thrombolysis  or  PA  is 
undertaken  with  the  primary  goal  of  achieving  coronary 
artery patency, which would be expected to prevent mural 
thrombi  by  preserving  the  viability  of  myocardium  and 
preventing  wall  motion  abnormalities.  No  TT  was  given 
during this patient’s stay in the local public hospital due to 
non-availability.  The  interventional  cardiologists  at  the 
Heart Institute of the  Caribbean (HIC) collectively made a 
decision not to attempt PA of the occluded infarct-related 
artery  based  on  the  evidence  from  occluded  artery  trial 
(OAT).
32 According to the OAT, late opening of the occluded 
infarct  related  artery  (3–28  days  after  AMI)  with 
percutaneous  coronary  intervention  was  not  associated 
with any improved clinical end points (reduced occurrence 
of  death,  re-infarction  or  heart  failure)  and  there  was  a 
trend toward excess re-infarction during a four-year follow-
up  period  and  hence  it  was  not  recommended  in  our 
patient. Repeat  echocardiograms  were done at six weeks 
and  three  months  with  the  three-month  study  showing 
complete resolution of the thrombus. Although there is no 
consensus regarding the time intervals to perform the serial 
echocardiograms  to  avoid  missing  the  diagnosis  of  late 
occurring LV thrombus, clinical judgment and consideration 
of other factors such as severity of AMI and LV dysfunction 
can be used to make the recommendation.  
 
In summary LV thrombus should be suspected in patients 
with large anterior wall MI. If not recognised and treated 
immediately,  it  can  result  in  life-threatening  embolic 
complications. Echocardiogram is a simple, inexpensive and 
non-invasive  technique  that  is  crucial  for  immediate 
diagnosis.  Effective  measures  should  be  taken  by  the 
various  stakeholders  to  provide  this  necessary  service  in 
public  hospitals  or  forge  a  meaningful  partnership  with 
better  equipped  private  sector  healthcare  providers  to 
make these services accessible to the population in a timely 
manner,  thereby  ensuring  that  patients  receive  evidence-
based medicine that takes advantage of advances in medical 
knowledge and technology. This will facilitate a reduction in 
the social and economic burden of cardiovascular disease 
and mortality associated with the disease. 
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